This video is sponsored by the Duke Clinical Medical Series.
Topics include:
* An Evidence-based Rationale for Successful Chronic Total Occlusion (CTO) Recanalization
* Cardiovascular Cath Lab Conference Case Presentation
* Case History
* http://cathlabconference.dcri.duke.edu/vidwin/pp/129/Slide16.swf
* Clinical Questions
* An Evidence-based Rationale for Successful Chronic Total Occlusion (CTO) Recanalization
* CTOs in Perspective
* CTOs in Perspective
* CTO Representation in DES Trials
* DES in CTO Revasc SES and PES Registries
The moderator, Peter Berger, MD, has indicated that he receives research/grant support
from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an
advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific
symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also
serves as Medical Director and has equity with Lumen, Inc.
The guest, David Kandzari, MD, has nothing to disclose regarding this CME activity.
|
|